CALL US NOW 020 7939 0780

Direct-acting Antiviral (DAA) treatment for Hepatitis C risks Hepatitis B reactivation

Direct-acting Antiviral (DAA) treatment for Hepatitis C risks Hepatitis B reactivation

New guidance from the Medicines and Healthcare products Regulatory Agency (MHRA) advises that all hepatitis C patients should be screened for hepatitis B before starting treatment with new Direct-acting Antivirals (DAAs). If patients are infected with both viruses this does not preclude treatment but this should be monitored and managed.

Read More

Westminster Justice Summit

The Haemophilia Society attended the Westminster Justice Summit today, hosted by Andy Burnham MP. At the event representatives from a large number of justice campaigns, including campaigners on contaminated blood shared their situations and challenges with the group. In his comments, Andy Burnham said there was a need to rebalance

Read More

The winter edition of the EHC newsletter is out now

The latest newsletter from the European Haemophilia Consortium is now available on their website. For the final issue of their comprehensive care and haemophilia spotlight of the year, they interview Prof Geoffrey Dusheiko, an emeritus professor of medicine at the Royal Free Hospital (London) and the University College London School

Read More

APPG Meeting with Jane Ellison and DH Officials

The APPG on Haemophilia and Contaminated Blood met with the Minister Jane Ellison to discuss the proposals in the consultation on support arrangements for people affected by contaminated blood. You can read our summary of the Jane Ellison meeting here

Read More